Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE: Telaprevir response-guided therapy in HCV
NCT00758043Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2008
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of telaprevir in hepatitis C (HCV), sponsored by Vertex Pharmaceuticals. Started Oct 2008; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00758043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758043.